Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,781 | 139 | 99.7% |
| Education | $9.38 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $620.73 | 26 | $0 (2024) |
| PFIZER INC. | $574.52 | 36 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $361.10 | 14 | $0 (2022) |
| AbbVie Inc. | $298.20 | 14 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $263.49 | 12 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $69.77 | 4 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $62.24 | 8 | $0 (2018) |
| Mylan Specialty L.P. | $51.70 | 2 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.53 | 3 | $0 (2022) |
| Allergan, Inc. | $48.18 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $202.52 | 10 | PFIZER INC. ($106.63) |
| 2023 | $511.53 | 21 | AstraZeneca Pharmaceuticals LP ($169.67) |
| 2022 | $179.75 | 9 | AstraZeneca Pharmaceuticals LP ($85.03) |
| 2021 | $743.71 | 33 | Biohaven Pharmaceuticals, Inc. ($237.27) |
| 2020 | $427.80 | 21 | Janssen Pharmaceuticals, Inc ($126.76) |
| 2019 | $229.64 | 17 | PFIZER INC. ($119.00) |
| 2018 | $231.50 | 17 | AstraZeneca Pharmaceuticals LP ($73.47) |
| 2017 | $263.64 | 13 | AstraZeneca Pharmaceuticals LP ($46.56) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: RESPIRATORY | ||||||
| 10/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/08/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $24.13 | General |
| Category: PSYCHIATRY | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Respiratory | ||||||
| 09/11/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/02/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Diabetes | ||||||
| 06/07/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/01/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.40 | General |
| 12/13/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: NEUROSCIENCE | ||||||
| 12/08/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/30/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/09/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $123.51 | General |
| Category: Respiratory | ||||||
| 11/08/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/25/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.93 | General |
| Category: NEUROSCIENCE | ||||||
| 10/13/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: NEUROSCIENCE | ||||||
| 10/05/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: PSYCHIATRY | ||||||
| 09/28/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/30/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: NEUROSCIENCE | ||||||
| 08/25/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/10/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/04/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: NEUROSCIENCE | ||||||
| 06/15/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 2,033 | 8,151 | $767,016 | $509,689 |
| 2022 | 31 | 2,668 | 7,011 | $606,784 | $389,255 |
| 2021 | 36 | 2,877 | 6,624 | $545,652 | $361,007 |
| 2020 | 31 | 2,442 | 5,482 | $389,237 | $253,691 |
All Medicare Procedures & Services
127 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 80 | 3,028 | $302,840 | $208,636 | 68.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 164 | 986 | $118,405 | $83,354 | 70.4% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 94 | 955 | $103,560 | $63,784 | 61.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 154 | 310 | $50,995 | $35,249 | 69.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 66 | 486 | $48,600 | $34,647 | 71.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 97 | 98 | $22,500 | $15,563 | 69.2% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 58 | 65 | $14,050 | $10,538 | 75.0% |
| 98929 | Osteopathic manipulative treatment, 9-10 body regions | Office | 2023 | 22 | 95 | $12,350 | $7,303 | 59.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 77 | 77 | $6,160 | $5,837 | 94.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 54 | $7,560 | $5,788 | 76.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 37 | $10,360 | $5,782 | 55.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 64 | 74 | $7,400 | $5,489 | 74.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 103 | 103 | $4,620 | $3,807 | 82.4% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 130 | 274 | $8,220 | $3,595 | 43.7% |
| 99344 | Residence visit for new patient with moderate level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 22 | 22 | $4,490 | $2,704 | 60.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 128 | 279 | $6,975 | $2,656 | 38.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 42 | $3,360 | $2,264 | 67.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 119 | 208 | $2,496 | $1,747 | 70.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 24 | 24 | $1,920 | $1,726 | 89.9% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 13 | 16 | $2,240 | $1,582 | 70.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 110 | 114 | $5,928 | $1,534 | 25.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 20 | 20 | $6,000 | $1,427 | 23.8% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 120 | 406 | $6,090 | $1,303 | 21.4% |
| 82274 | Stool analysis for blood, by fecal hemoglobin determination by immunoassay | Office | 2023 | 57 | 57 | $2,565 | $889.20 | 34.7% |
| 93701 | Measurement of heart blood flow and respiration | Office | 2023 | 24 | 24 | $2,400 | $703.20 | 29.3% |
About Dr. Norman Chow, D.O
Dr. Norman Chow, D.O is a Family Medicine healthcare provider based in Los Gatos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871666248.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Norman Chow, D.O has received a total of $2,790 in payments from pharmaceutical and medical device companies, with $202.52 received in 2024. These payments were reported across 141 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,781).
As a Medicare-enrolled provider, Chow has provided services to 10,020 Medicare beneficiaries, totaling 27,268 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 127 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Los Gatos, CA
- Active Since 11/15/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1871666248
Products in Payments
- FARXIGA (Drug) $463.52
- XARELTO (Drug) $343.72
- NURTEC ODT (Drug) $314.02
- ELIQUIS (Drug) $220.96
- COLOGUARD (Device) $153.99
- UBRELVY (Drug) $142.18
- BREZTRI (Drug) $139.81
- VRAYLAR (Drug) $111.44
- EUCRISA (Drug) $108.93
- COLOGUARD DNA CAPTURE REAGENTS (Device) $71.39
- BELSOMRA (Drug) $69.77
- Yupelri (Drug) $51.70
- REXULTI (Drug) $47.88
- GENERAL - PAIN MANAGEMENT (Device) $45.97
- VIBERZI (Drug) $44.66
- JARDIANCE (Drug) $38.43
- CONTRAVE (Drug) $36.59
- QULIPTA (Drug) $34.99
- XIFAXAN (Drug) $26.31
- Amitiza (Drug) $25.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Los Gatos
Jennifer Haggerty, M.d, M.D
Family Medicine — Payments: $6,952
Rodney Gin, M.d, M.D
Family Medicine — Payments: $6,901
Dr. J Zimmer, Md, MD
Family Medicine — Payments: $5,030
Dr. Mary Defigard, Md, MD
Family Medicine — Payments: $4,173
Dr. Kathryn Shade, M.d, M.D
Family Medicine — Payments: $2,886
Dr. Tiffany Davies, M.d, M.D
Family Medicine — Payments: $2,734